Claims for Patent: 9,999,593

Summary for Patent: 9,999,593

Title:	Method and composition for treating ocular hypertension and glaucoma
Abstract:	The present invention relates to an ophthalmic aqueous composition containing PGF2.alpha. analogs for treating ocular hypertension and glaucoma, to a method for treating ocular hypertension and glaucoma by administering said composition to a subject in need of such treatment, and to a method for increasing aqueous solubility and stability of PGF2.alpha. analogs in an aqueous composition.
Inventor(s):	Reunamaki; Timo (Tampere, FI), Pellinen; Pertti (Lempaala, FI), Oksala; Olli (Tampere, FI), Lehmussaari; Kari (Tampere, FI)
Assignee:	SANTEN PHARMACEUTICAL CO., LTD. (Osaka-shi, Osaka, JP) ASAHI GLASS CO., LTD. (Chiyoda-Ku, Tokyo, JP)
Application Number:	12/995,351
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,999,593
Patent Claims:	1. An aqueous ophthalmic solution consisting of: 0.0015% w/v tafluprost; 0.075% w/v polysorbate 80; 0.05% w/v disodium edetate; 2.25% w/v glycerol; 0.2% w/v sodium dihydrogen phosphate dihydrate; pH adjusters; and water wherein the solution is filled in a unit dose container and wherein the container is a low density polyethylene container which contains no more than 10% of any material other than polyethylene. 2. The aqueous ophthalmic solution according to claim 1, wherein the container is filled with 0.3 mL of the aqueous ophthalmic solution. 3. The aqueous ophthalmic solution according to claim 1, wherein the container is manufactured by extrusion blow moulding method. 4. The aqueous ophthalmic solution according to claim 1, wherein an amount of the aqueous ophthalmic solution in the container falls within a range of from 0.2 to 0.5 mL. 5. The aqueous ophthalmic solution according to claim 1, wherein less than 10% of said tafluprost is absorbed when the aqueous solution is stored at 40 degree Celsius for four weeks in the container. 6. The aqueous ophthalmic solution according to claim 1, wherein the container contains no material other than polyethylene. 7. The aqueous ophthalmic solution according to claim 6, wherein the material other than polyethylene is selected from the group consisting of polypropylene, polyethylene terephthalate, polyvinyl chloride, acrylic resins, polystyrene, polymethyl methacrylate and nylon 6.